Key result
Combining hiPSC-CMs and AI predicts drug-induced proarrhythmic risk with a superior ~0.98 ROC-AUC.
Why the study?
Cardiotoxicity remains the leading cause of drug attrition, but its prediction is suboptimal with conventional hERG assays and animal models.
Does an integrated platform combining hiPSC-CMs with AI-driven modeling improve the prediction of drug-induced proarrhythmic risk?
Does an integrated platform combining hiPSC-CMs with AI-driven modeling improve the prediction of drug-induced proarrhythmic risk?
Answers are grounded in this paper and cite their sources.
An AI-driven platform using hiPSC-CMs accurately predicts drug-induced proarrhythmic risk, detecting functional cardiotoxicity that is often missed by standard viability assays.
Cardiotoxicity remains the leading driver of drug attrition; however, its prediction remains suboptimal when conventional hERG assays and animal models are used. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer a human-relevant alternative that aligns with the CiPA initiative and ICH E14/S7B guidelines. This study validated an integrated platform that combines high-purity hiPSC-CMs with Artificial Intelligence (AI) to enhance the accuracy of predicting drug-induced proarrhythmic risk. Phenotypic characterization of the hiPSC-CMs demonstrated high cardiac differentiation efficiency (cTnT + > 95%) and a predominant ventricular-like identity (MLC-2 V + , 78-84%), ensuring biological relevance for ventricular arrhythmia assessment. Electrophysiological data from 28 CiPA reference compounds were collected via Multielectrode Array (MEA) to train multiple machine learning models. The Artificial Neural Network outperformed the other architectures, achieving a superior ROC-AUC of 0.982. The utility of the platform was evaluated using 12 anticancer agents. Although most drugs showed dose-dependent reductions in impedance-based viability, four compounds (Idarubicin, Erlotinib, Sunitinib, Cyclophosphamide) did not exhibit overt structural cytotoxicity. However, MEA analysis revealed significant functional perturbations, including FPDcF prolongation, in sunitinib- and erlotinib-treated samples after long-term treatment. The AI model subsequently classified these two agents as high-to-intermediate risk for Torsades de Pointes (TdP), thereby quantifying their time-dependent proarrhythmic liabilities. These findings show the platform's ability to detect hidden functional cardiotoxicity, often missed by standard viability assays. The AI-hiPSC-CM system offers a high-throughput, early-stage safety screening tool that bridges in vitro data and clinical outcomes with a standardized risk assessment framework.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) studied Drug-induced cardiotoxicity. AI-integrated hiPSC-CM platform (Artificial Neural Network) vs. Conventional single-biomarker (FPDcF) analysis was evaluated on ROC-AUC for predicting Torsades de Pointes (TdP) risk (ROC-AUC 0.982). An integrated platform combining high-purity hiPSC-cardiomyocytes with an Artificial Neural Network achieved a superior ROC-AUC of 0.982 for predicting drug-induced proarrhythmic risk.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: